Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal to buy Kashiv BioSciences for $375 million cash plus stock; raises 2026 guidance

Positive Impact 4 of 5 m&a Written later

Amneal agreed on April 21, 2026 to acquire 100% of Kashiv BioSciences, LLC for $375 million in cash and 28,942,108 Class A shares at closing, plus up to $350 million in contingent regulatory milestone payments and royalties. The same day, Amneal reported preliminary first quarter 2026 results showing higher revenue, net income and EPS, and raised its 2026 adjusted EBITDA and adjusted diluted EPS guidance.

Key points

  • Consideration: $375 million cash and 28,942,108 Class A shares at closing, plus up to $350 million in contingent regulatory milestone payments; closing expected in the second half of 2026 and requires Amneal shareholder approval.
  • Preliminary Q1 2026 (unaudited): consolidated net revenue $723 million, up 4% from $695 million; net income $78 million versus $25 million; diluted EPS $0.19 versus $0.04.
  • Raised 2026 adjusted EBITDA guidance to $740 million-$770 million from $720 million-$760 million; adjusted diluted EPS to $0.95-$1.05 from $0.93-$1.03; net revenue guidance unchanged at $3.05 billion-$3.15 billion.
  • Acquisition agreement has an outside date of November 17, 2026, extendable to January 12, 2027 if only certain regulatory approvals remain outstanding.

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECApr 22, 2026, 6:22 AM ET
Accession number0001193125-26-168231

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.